SCHEMBL2903056

SCHEMBL2903056

O=CCN1CCN(C(=O)/C=C/c2cccc(Cl)c2)CCC1=O

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
LMNA P02545 2/20 0.53
ALDH1A1 P00352 1/20 0.53
CYP1A2 P05177 1/20 0.49
CYP2C9 P11712 1/20 0.49
GPR183 P32249 4/20 0.46
ACHE P22303 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.43
GAA P10253 2/20 0.43
MAPT P10636 1/20 0.43
ITGB2 P05107 1/20 0.43
ICAM1 P05362 1/20 0.43
ITGAL P20701 1/20 0.43
MAPK1 P28482 1/20 0.43
USP2 O75604 1/20 0.43
RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2903059 1.00 MEN1 (0.53) MEN1KMT2ALMNAALDH1A1CYP1A2
SCHEMBL2897188 0.87 MEN1 (0.56) MEN1KMT2ALMNAALDH1A1CYP1A2
SCHEMBL2904456 0.87 NPC1 (0.57) GPR183MAPTITGB2ICAM1ITGAL
SCHEMBL2902131 0.87 MEN1 (0.53) MEN1KMT2ALMNAALDH1A1CYP1A2
SCHEMBL2902128 0.87 MEN1 (0.53) MEN1KMT2ALMNAALDH1A1CYP1A2
SCHEMBL2904454 0.87 NPC1 (0.57) GPR183MAPTITGB2ICAM1ITGAL
SCHEMBL2897190 0.87 MEN1 (0.56) MEN1KMT2ALMNAALDH1A1CYP1A2
SCHEMBL2904334 0.84 MEN1 (0.51) MEN1KMT2ALMNAALDH1A1CYP1A2
SCHEMBL2904336 0.84 MEN1 (0.51) MEN1KMT2ALMNAALDH1A1CYP1A2
SCHEMBL1555710 0.83 ALDH1A1 (0.50) MEN1KMT2ALMNAALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2010506-B1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS HOFFMANN LA ROCHE (CH) 2010-08-04 EP disclosed
US-7632829-B2 Diazepan derivatives HOFFMANN-LA ROCHE INC. (US) 2009-12-15 US disclosed
EP-2010506-A1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-Roche AG (CH) 2009-01-07 EP disclosed
WO-2007122103-A1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2007-11-01 WO disclosed
US-20070249589-A1 Novel diazepan derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249589-A1 Novel diazepan derivatives CCR3, CCR1, CCR10 MEN1 2072/4885KMT2A 2954/4885LMNA 3307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.